Blueprint is an independent publisher and comparison service, not an investment advisor. The information provided is for educational purposes only and we encourage you to seek personalized advice from qualified professionals regarding specific financial decisions. Past performance is not indicative of ...
vs. an increase of about 40%for the S&P 500 over this roughly 3-year period. However, the increase in DB stock has been far from consistent. Returns for the stock were 15% in 2021, -8% in 2022, and 18% in 2023. In comparison,...
However, the increase in these stocks has been far from consistent. Returns for EBAY stock were 34% in 2021, -36% in 2022, 8% in 2023, and 49% so far in 2024, while that for LULU stock were 12%, -18%, 60%, and -22%, respectively. In comparison, returns for the S&P 500 hav...
The table above shows the dividend yield for both funds. This table shows that QQQ has a historical advantage in 2022 and 2021 with a higher dividend yield. But YTD in 2023, QQM has a slight advantage. This can be a sign that as the QQQM fund becomes more mature, it will be able t...
| $usd | post-market: $30.58 +0.14 ( +0.45% ) 7:55 pm summary holdings ratings momentum expenses dividends risk liquidity peers options charting all all analysis analysis comments comments news news press releases press releases related analysis related analysis charts 1d 5d 1m 6m ytd 1y 5y ...
1D 5D 1M 6M YTD 1Y 5Y 10Y MAX +4.94% NASDAQ BulletShares High Yield Ladder Index 7 Year Total Return price and volume Combination chart with 2 data series. Chart represents NASDAQ BulletShares High Yield Ladder Index 7 Year Total Return price and volume over 1Y pe...
YTD+10.80% 1 month+8.96% 3 months+11.94% 6 months+4.46% 1 year+26.13% 3 years- 5 years- Since inception (MAX)+74.83% 2024+18.98% 2023+59.62% 2022- 2021- Monthly returns in a heat map Risk Risk metrics in this section: Volatility, annualised, measured for 1, 3 and 5 year period...
Akari Therapeutics CEO quits over retracted drug comparison May. 30, 2017 at 8:07 p.m. ETby Maria Armental Akari Therapeutics stock rises 10% on positive mid-stage trial results Apr. 24, 2017 at 7:25 a.m. ETby Emma Court Akari Therapeutics stock rises 10% on positive mid-stage trial...
5 Day -10.19% 1 Month -16.21% 3 Month -25.38% YTD -20.49% 1 Year -58.55% Analyst Ratings Sell Under Hold Over Buy Number of Ratings 1 Full Ratings Recent News MarketWatch Dow Jones Akari Therapeutics started at buy with $4 stock price target at Alliance Global Nov. 1, 2022 ...
YTD MAX 17/02/2024 - 17/02/2025 Agregar ETF para comparar Mostrar más configuraciones de gráficos Básico Datos Índice Nasdaq 100® Foco de la inversión Acciones, Estados Unidos, Tecnología Patrimonio del fondo EUR 3.204 m Gastos corrientes ...